Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 04.03.2024 3 BMC Pediatr 3 BMJ 1 Clin Infect Dis 1 J Gen Virol 3 J Infect Dis 1 J Virol 2 JAMA 2 Lancet 3 MMWR Morb Mortal Wkly Rep 1 N Engl J Med 1 Nat Med 1 Pediatrics 1 PLoS Comput Biol 7 PLoS One 1 Proc Natl Acad Sci U S A 1 Science 23 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. ZHU J, Cheng W, Xu Y, Guo Y, et al
   Two cases of small bowel necrosis due to intussusception secondary to abnormal proliferation of intestinal Peyer's patches in infants after MMR vaccination.
   BMC Pediatr. 2024;24:147.
   PubMed         Abstract available
   
   
2. GETA M, Yizengaw E, Manyazewal T
   Hepatitis B vaccine effectiveness among vaccinated children in Africa: a systematic review and meta-analysis.
   BMC Pediatr. 2024;24:145.
   PubMed         Abstract available
   
   
3. SAYINZOGA F, Hirschhorn LR, Ntawukuriryayo JT, Beyer C, et al
   Understanding rapid implementation from discovery to scale: Rwanda's implementation of rotavirus vaccines and PMTCT in the quest to reduce under-5 mortality.
   BMC Pediatr. 2024;23.
   PubMed         Abstract available
   
   

   
   BMJ

4. WISE J
   Covid-19 taskforce called for a new national vaccine agency to prepare for future pandemics.
   BMJ. 2024;384:q534.
   PubMed        
   
   
5. TAYLOR L
   Dengue fever: Brazil rushes out vaccine as climate change fuels unprecedented surge.
   BMJ. 2024;384:q483.
   PubMed        
   
   
6. WISE J
   Covid-19: Two rare vaccine side effects detected in large global study.
   BMJ. 2024;384:q488.
   PubMed        
   
   

   
   Clin Infect Dis

7. SHAH MM, Joyce B, Plumb ID, Sahakian S, et al
   Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19.
   Clin Infect Dis. 2024 Feb 27:ciae105. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Gen Virol

8. RAO S, Erku D, Mahalingam S, Taylor A, et al
   Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials.
   J Gen Virol. 2024;105.
   PubMed         Abstract available
   
   

   
   J Infect Dis

9. CAO Y, Hayashi CTH, Kumar N
   A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei.
   J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093.
   PubMed         Abstract available
   
   
10. WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al
    A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diverse Klebsiella pneumoniae isolates.
    J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093.
    PubMed         Abstract available
    
    
11. DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al
    Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Chlamydia-Infected Women with Different Chlamydia Outcomes.
    J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

12. GEORGANA I, Scutts SR, Gao C, Lu Y, et al
    Filamin B restricts vaccinia virus spread and is targeted by vaccinia virus protein C4.
    J Virol. 2024 Feb 27:e0148523. doi: 10.1128/jvi.01485.
    PubMed         Abstract available
    
    

    
    JAMA

13. ANDERSSON NW, Thiesson EM, Hviid A
    Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines.
    JAMA. 2024 Feb 26:e241036. doi: 10.1001/jama.2024.1036.
    PubMed        
    
    
14. JAMIESON KH, Johnson KB, Cappola AR
    Misinformation and the Vaccine Adverse Event Reporting System.
    JAMA. 2024 Feb 26. doi: 10.1001/jama.2024.1757.
    PubMed        
    
    

    
    Lancet

15. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    PubMed        
    
    
16. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

17. ZHU S, Quint J, Leon TM, Sun M, et al
    Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:175-179.
    PubMed         Abstract available
    
    
18. DECUIR J, Payne AB, Self WH, Rowley EAK, et al
    Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged >/=18 Years - VISION and IVY Networks,
    MMWR Morb Mortal Wkly Rep. 2024;73:180-188.
    PubMed         Abstract available
    
    
19. FRUTOS AM, Price AM, Harker E, Reeves EL, et al
    Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States.
    MMWR Morb Mortal Wkly Rep. 2024;73:168-174.
    PubMed         Abstract available
    
    

    
    N Engl J Med

20. MONTO AS, Zambon M, Weir JP
    The End of B/Yamagata Influenza Transmission - Transitioning from Quadrivalent Vaccines.
    N Engl J Med. 2024 Feb 28. doi: 10.1056/NEJMp2314801.
    PubMed        
    
    

    
    Nat Med

21. PERETTI-WATEL P, Verger P, Ward JK
    To understand mRNA vaccine hesitancy, stop calling the public anti-science.
    Nat Med. 2024 Feb 27. doi: 10.1038/s41591-024-02816.
    PubMed        
    
    

    
    Pediatrics

22. O'LEARY ST, Opel DJ, Cataldi JR, Hackell JM, et al
    Strategies for Improving Vaccine Communication and Uptake.
    Pediatrics. 2024;153:e2023065483.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

23. VALEGA-MACKENZIE W, Rodriguez Messan M, Yogurtcu ON, Nukala U, et al
    Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine.
    PLoS Comput Biol. 2024;20:e1011247.
    PubMed         Abstract available
    
    

    
    PLoS One

24. WU S, Li Y, Baral S, Mishra S, et al
    Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada.
    PLoS One. 2024;19:e0299304.
    PubMed         Abstract available
    
    
25. BASHIR IM, Al-Waleedi AA, Al-Shaibani SM, Rajamanar M, et al
    Strengthening laboratories in response to outbreaks in humanitarian emergencies and conflict settings: Results, challenges and lessons from expanding PCR diagnostic capacities for COVID-19 testing in Yemen.
    PLoS One. 2024;19:e0298603.
    PubMed         Abstract available
    
    
26. DIAS E, Diniz AMA, Souto GR, Guerra HL, et al
    Predicting COVID-19 cases in Belo Horizonte-Brazil taking into account mobility and vaccination issues.
    PLoS One. 2024;19:e0269515.
    PubMed         Abstract available
    
    
27. KONLAN MY, Mahama F, Abubakari BB, Konka P, et al
    Predictors of vaccination card retention in Tamale Metropolis, Ghana.
    PLoS One. 2024;19:e0292765.
    PubMed         Abstract available
    
    
28. 
    Retraction: Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza Virus.
    PLoS One. 2024;19:e0300096.
    PubMed        
    
    
29. HOU Y, Bidkhori H
    Multi-feature SEIR model for epidemic analysis and vaccine prioritization.
    PLoS One. 2024;19:e0298932.
    PubMed         Abstract available
    
    
30. ABER JO, Bongomin F, Opio SL, Ochola E, et al
    Hepatitis B vaccine uptake and associated factors among adults of Gulu city in Northern Uganda: A community-based cross-sectional study.
    PLoS One. 2024;19:e0297617.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. CHANG S, Shin KS, Park B, Park S, et al
    Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.
    Proc Natl Acad Sci U S A. 2024;121:e2313681121.
    PubMed         Abstract available
    
    

    
    Science

32. PAWAR P
    World's cholera vaccine stash is empty-but relief is on its way.
    Science. 2024;383:939-940.
    PubMed         Abstract available
    
    

    
    Vaccine

33. LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
    Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
    Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
34. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
35. OMAR ALI S, Dessart C, Parikh R
    Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
36. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
37. ZHOU W, Guo X, Lu J, Lu X, et al
    Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
    Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
38. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
39. JACKSON S, Kabir Z, Comiskey C
    Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
    Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
40. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
41. PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
    What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
    Vaccine. 2024;42:1065-1070.
    PubMed         Abstract available
    
    
42. DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
    Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
    Vaccine. 2024;42:1094-1107.
    PubMed         Abstract available
    
    
43. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    PubMed         Abstract available
    
    
44. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
45. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
46. BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
    Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
    Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
47. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
48. HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
    Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
    Vaccine. 2023;41 Suppl 2.
    PubMed        
    
    
49. FLANDES X, Hansen CA, Palani S, Abbas K, et al
    Vaccine value profile for Chikungunya.
    Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
50. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
51. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    PubMed        
    
    
52. KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
    Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
53. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
54. GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
    Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
55. TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
    Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.